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ABSTRAK
Tujuan: untuk menilai manfaat pemeriksaan alpha-1-acid glycoprotein (AAG) untuk mendiagnosis 
karsinoma hepatoselular (KHS), dan dalam kombinasi dengan alpha fetoprotein (AFP) sebagai bagian 
dari pemeriksaan rutin pada pasien sirosis hati. Metode: penelitian ini merupakan studi diagnostik dengan 
menggunakan desain potong lintang. Sebanyak 106 pasien diikutsertakan dalam penelitian ini. Data dasar 
seperti usia, jenis kelamin, kadar AFP, kadar AAG, pemeriksaan darah tepi, SGOT dan SGPT diambil secara 
kolektif dari pasien sirosis hati dengan atau tanpa KHS. Pemeriksaan kadar AAG serum dihitung dengan 
metode immunoturbodimetric assay dan pemeriksaan kadar AFP  dengan enzyme immune assay. Analisis 
statistikal dilakukan dengan menggunakan SPSS 13.0. Perbandingan data antar grup dilakukan dengan uji 
Mann-Whitney. Nilai diagnostik masing-masing penanda dibandingkan secara paralel pada kasus KHS. 
Hasil: analisis receiver operating characteristic (ROC) menunjukkan area di bawah kurva untuk kombinasi AFP 
dan AAG sebesar 88.1%, lebih tinggi dibandingkan AFP saja (86.2%) atau AAG saja (76.5%) dengan sensitivitas 
83%, 73% dan 44% pada spesifisitas >80%. Kesimpulan: penelitian ini memperlihatkan perbandingan peran 
pemeriksaan AAG, AFP, dan kombinasi keduanya dalam mendiagnosis KHS pada pasien sirosis hati. Kombinasi 
AFP dan AAG dapat digunakan untuk deteksi dini dan penapisan KHS.
Kata kunci: alfa fetoprotein, alfa-1-acid glikoprotein, penanda biokimia, kanker hati.
ABSTRACT
Aim: to evaluate the use of alpha-1-acid glycoprotein (AAG) for diagnosing hepatocellular carcinoma 
(HCC), and to combine with alpha fetoprotein (AFP) as part of routine examination in liver cirrhosis patients. 
Methods: this is a diagnostic study using cross-sectional design. A hundred and six patients were included in this 
study. Baseline data such as age, gender, AFP, AAG, peripheral blood count, AST and ALT were consecutively 
collected from liver cirrhosis patients with or without HCC. Serum AAG were measured quantitatively using 
immunoturboditimetric assay and AFP with enzyme immune assay (EIA). Statistical analysis were done using 
SPSS 13.0. Data comparisons between group were done using Mann-Whitney test. Diagnostic performance for 
each marker alone was compared to the surrogate use of both markers (combined parallel approach) in HCC 
cases. Results: receiver operating characteristic (ROC) analysis showed that area under the curve for AFP-
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AAG combination was 88.1% and higher than AFP only (86.2%) or AAG only (76.5%) with sensitivity of 83%, 
73% and 44%, respectively, at specificity of >80%. Conclusion: our study showed that combination of AFP 
and AAG is superior than either marker alone in diagnosing HCC in liver cirrhosis patients. Combination of 
AFP and AAG may be used to prompt early diagnosis screening of HCC.
Key words: alpha fetoprotein, alpha-1-acid glycoprotein, biomarker, liver cancer.
INTRODUCTION
Hepatocellular Carcinoma (HCC) is the 
second most common cause of death from cancer 
worldwide, estimated to be responsible for 
nearly 746,000 deaths in 2012 (9.1% of the total) 
(globoscan, 2012).1 Most of the HCC incidence 
occurred in developing countries, particularly in 
Asia and Africa which are susceptible to hepatitis 
B and hepatitis C. However, recent trends indicate 
that incidence of HCC in developed countries is 
increasing.2 This could be explained by changes 
in the prevalence of hepatitis. Screening for HCC 
can lead to early diagnosis and treatment.
In most of the cases, HCC is diagnosed in 
its advanced stage that the treatment options 
are limited with lower survival rates. It means 
that diagnosing HCC in its early stage is of 
the utmost importance. Based on a systematic 
review, several serum biomarkers can be used 
to detect HCC.3 Alpha fetoprotein (AFP) is 
the most widely studied screening test for 
detecting HCC. The normal range for serum 
AFP levels is 10-20 ng/mL and a level > 400 ng/
mL is usually regarded as diagnostic for HCC. 
Although Asia-Pacific Association for Study of 
the Liver (APASL) consensus used lower level 
of AFP (>200 ng/mL) for diagnosis of HCC, 
some reports have indicated that the high serum 
concentration of AFP correlates with the poor 
prognosis of HCC patients. However, two thirds 
of HCC patients with the nodule less than 4 cm 
have serum AFP levels less than 200 ng/mL and 
up to 20% HCC patients do not produce AFP.4
It has been recognized that AFP has a 
low sensitivity in detection of HCC. APASL 
guidelines 2010 do not recommend the use 
of AFP only for diagnosing HCC. Additional 
investigations are needed to establish the 
diagnosis.3 AAG is an acute phase protein with 
normal levels of 50-120 mg/dL. This serum 
concentration increases in response to systemic 
tissue injury, inflammation or infection, and 
these changes in serum protein concentrations 
have been correlated with increases in hepatic 
synthesis.5 Raised levels of AAG were found 
in 80.6% of patients with hepatoma compared 
to 20% of patients with cirrhosis and only 5.7% 
of patients with hepatitis.6 Our group found that 
AAG was a potential biomarker in the diagnosis 
of HCC.7,8 In a study with 220 patients, of which 
96 were control and 124 were HCC cases (61 
were AFP-low and 63 were AFP-high), it was 
found that Alpha-1-acid glycoprotein (AAG) 
was more predictive of AFP-low HCC than of 
AFP-high HCC.7 The other study, combination 
between AFP and AAG could significantly 
improve the diagnostic accuracy. ROC analysis 
of AFP in combination with AAG yielded AUC 
(area under curve) value higher (0.943) than AFP 
alone (0.750) or AAG (0.907) alone.8
Our previous study showed AAG and AFP 
combination was a good biomarker for diagnosis 
of HCC. However, AAG determination in 
the previous study were measured with high 
performance liquid chromatography (HPLC) 
that can be done only in a research center and 
not routinely available in clinical laboratories. 
Furthermore, the subjects from previous studies 
did not specifically liver cirrhosis patients whom 
the risk of developing HCC are the greatest. 
In this study the quantitative measurement 
of serum AAG was done with nephelometric 
(immunoturbidimetric) assay in routine clinical 
laboratorium. The subjects of this study were 
liver cirrhosis patients with HCC and compare 
it with liver cirrhosis patients without HCC. The 
objective of this study was to evaluate the use 
of AAG in routine laboratory as biomarker for 
screening of HCC among liver cirrhosis patients 
in combination with AFP.
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METHODS
This is a cross-sectional study. The subjects 
of this study were liver cirrhotic patients, aged 
18 years and older. Diagnosis of hepatocellular 
carcinoma in the subjects group were defined 
according to AASLD guidelines on hepatocellular 
carcinoma9 or by presence of liver nodule, AFP 
>200 ng/mL and supported with two imaging 
results with typical features of hepatocellular 
carcinoma. We included liver cirrhotic patients 
without liver nodule as control group in this study. 
A total of 106 patients who regularly followed up 
at Hepatobiliary Division, Department of Internal 
Medicine, Cipto Mangunkusumo Hospital, 
Indonesia between January to August 2013 who 
meet the criteria were consecutively enrolled and 
serum samples were collected. For each patient, 
clinical data, including age, sex, AFP value, 
AAG, hemoglobin, leukocyte, thrombocyte, 
AST, and ALT were obtained. Diagnosis of 
HCC relied on the presence of malignant liver 
nodule, as established on imaging techniques 
according to APASL criteria or by pathological 
analysis of liver biopsy, if necessary. Patients 
with other type of malignancies, without evident 
of liver cirrhosis, diagnosed with ongoing acute 
infections (pneumonia, colitis, acute hepatitis, 
sepsis or HIV), pregnant women, under treatment 
of corticosteroid, or recently recovered from 
surgery, trauma and myocardial infarction were 
excluded from the study. Among 106 patients, 
59 patients had cirrhosis with HCC and the 
other 47 patients had cirrhosis without HCC as 
negative control to HCC group. All patients gave 
informed consent to participate in the study and 
the protocol was approved by ethical committee 
of Faculty of Medicine, University of Indonesia, 
Jakarta.
Test Methods
A 10 mL blood sample were collected in 
serum separator tube and stored at ≤ -20oC until 
AFP and AAG measurement.
Alpha Fetoprotein Measurement
Alpha fetoprotein measurement remain the 
reference serum biomarker test in diagnosing 
HCC. The quantitative measurement of plasma 
AFP was performed using ADVIA Centaur AFP 
assay, a two-site sandwich immunoassay using 
direct chemiluminometric technology, which 
uses constant amounts of two antibodies. The 
first antibody is an affinity purified polyclonal 
rabbit anti-AFP antibody labeled with acridinium 
ester. The second antibody, in the solid phase, is a 
monoclonal mouse anti-AFP antibody covalently 
coupled to paramagnetic particles. After blood 
sample collection, blood samples were allowed 
to clot adequately before centrifugation, while 
keeping the keep tubes stoppered and upright 
all times. For condition when assay was not 
completed within 48 hours, the specimen was 
refrigerated at or below -20oC. When samples 
were ready for the assay, 10 μL of sample was 
dispensed into a cuvette. As much as 50 μL of 
lite reagent and 250 μL of solid phase were 
dispensed and incubated for 7.5 minutes at 37oC. 
The cuvettes were then separated, aspirated, 
and washed using reagent water. Not less than 
300 μL each of acid reagent and base reagent 
were dispensed to initiate the chemiluminescent 
reaction. A direct relationship exists between 
concentration of AFP present in patient sample 
and the amount of relative light units (RLUs) 
detected by the system. The results were reported 
in ng/mL with cutoff value of ≤15 ng/mL.
Alpha-1-acid Glycoprotein Measurements
Quantitative measurement of plasma 
AAG concentration was performed using 
immunoturbidimetric assay by Roche/Hitachi 
Cobas C system. After collection, blood samples 
were allowed to clot adequately for 30 minutes 
before centrifugation. Samples were centrifuged 
at 1500 g for 10 minutes before performing the 
assay. The serum supernatant was extracted 
and dispensed into sample cup. Anti-α1-acid 
glycoprotein  antibodies react with antigen in 
the sample to form an antigen/antibody complex. 
Following agglutination, this is measured 
turbidimetrically using cut-off value of 3.25 g/L. 
Statistical Analysis
Statistical analysis were done using SPSS 
13.0. Descriptive measures were determined for 
each variable in every group, presented in mean ± 
SD. Data comparisons between group were done 
using Mann-Whitney test. Spearman correlation 
coefficient (r) was applied to our result. A p-value 
<0.05 was considered statistically significant. 
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For choosing the best cut off value, receiver 
operator characteristic (ROC) curve was 
generated and the Youden’s index was calculated. 
The best cut off values had the highest Youden 
indices. Diagnostic performance for each marker 
alone (diagnostic specificity, sensitivity, positive 
and negative predictive values) was compared 
to the surrogate use of both markers (combined 
parallel approach) in HCC cases.
RESULTS
Baseline data of the patients can be seen in 
Table 1. There was not significant difference in 
the mean age between HCC dan cirrhosis.
AFP serum in patients with HCC and 
cirrhosis (mean: 34923.96ng/ml, SD: 80301.31 
ng/ml) was significantly higher than patients with 
cirrhosis (mean: 31.53 ng/ml, SD: 169.98 ng/ml, 
|p = 0.0005, Mann Whitney test). As well as AFP, 
AAG serum in HCC patients (mean: 117.59 mg/
dL, SD: 60.95 mg/dL) was significantly higher 
than in cirrhosis patients (mean: 66.78 mg/dL, 
SD: 44.84 mg/dL, p=0.0005, Mann Whitney 
test).There was no correlation between AFP 
and AAG in all patients (r=0.172; p=0.079, 
correlation test) and between HCC and cirrhosis 
patients only (r=-0.038; p=0.773; spearman 
correlation test, Figure 1).
To evaluate the diagnostic value of serum 
AFP and AAG, AUC value from ROC curve 
were performed (Figure 2). AUC value in AFP 
was 86.2% while AUC in AAG was 76.5%. 
Combination AFP and AAG produce the highest 
AUC value (88.1%) compared to AFP only 
or AAG only. At >80% specificity, the AFP 
sensitivity was 73% in cut off 20.45 ng/ml and 
Table 1. Clinical characteristics of patients
Clinical features HCC + Cirrhosis (n=59) Cirrhosis (n=47)
Age-year (mean+SD) 55.53+12.01 55.60+11.59
Gender (% male/female) 84.7/15.3 55.3/44.7
Hemoglobin (mean+SD) 11.70+2.22 11.33+1.69
Leucocyte (mean+SD) 9538.97+6612.86 6625.53+2600.99
Thrombocyte (mean+SD) 232503.1+139378.0 123723.4+64576.5
AST (mean+SD) 171.93+216.30 63.74+46.46
ALT (mean+SD) 86.31+117.92 49.68+31.19
Hepatitis B (% Y/N) 33.9/66.1 32/68
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Figure 1. Scatter plot of AFP and AAG (no correlation) in all patients (left). Scatter plot of AFP and AAG (no correlation) within 
HCC and cirrhosis patients (right).
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AAG sensitivity was 44% in cut off 129 mg/dL. 
Combination AFP and AAG have the highest 
sensitivity (85%) compared to the other (Table 2).
DISCUSSION
The prognosis and survival of patients with 
HCC is highly depend on the stage of disease 
at the time of diagnosis. Hence, the role of 
screening assay would be beneficial in detecting 
early stage of HCC. A review of studies showed 
that AFP, DCP, AFP-L3 and GPC3 can be used as 
serum marker for HCC.3 AFP is not a sufficient 
reliable marker to identify HCC patients due to 
its poor sensitivity.
Wang CS et. al10 found that DCP has a better 
diagnostic value than AFP in differentiating HCC 
from nonmalignant chronic liver disease, with 
AUC value of 85% and 73% respectively (among 
patients with non-cirrhotic chronic hepatitis, 
compensated cirrhosis, and HCC).10 On the other 
hand, Nakamura S (2006) found that the AUC 
value of DCP was significantly smaller than AFP 
in tumor less than 3 cm in diameter (p<0.0001) 
and was significantly larger than AFP in tumor 
greater than 5 cm in diameter (p<0.0001), with 
chronic hepatitis or cirrhosis as control.11
AFP-L3 is a fucosylated variant of AFP that 
reacts with lens culinaris agglutinin A and can 
differentiate an increase in AFP due to HCC 
from that in patients with benign liver disease.3 
The incidence of HCC was significantly higher 
in patients with elevated AFP-L3% compared 
to those with elevated AFP.12 Subwongcharoen 
S et al. found that the AUC value for diagnosis 
of HCC with AFP (71%) is higher than AFP-L3 
(67%). In addition, the serum level of AFP was 
significantly different between the small mass 
(occupying lesser than 50% of liver volume) and 
large mass (occupying more than 50% of liver 
volume) of HCC (p=0.040).13




















































Vol 47 • Number 3 • July 2015                                      Performance of alpha fetoprotein in combination with AAG 
221
A meta-analysis of serum markers for diagnosis 
of HCC from 40 studies was established. AFP was 
considered to be the reference biomarker. It was 
shown that the AUC of combination AFP+DCP 
(0.874), were superior to the reference AFP 
biomarker (Table 3).14 GPC3 is a heparan sulfate 
proteoglycan anchored to the plasma membrane. 
It has been reported that GPC3 messenger RNA 
levels were increased in HCC.3 However, Ozkan 
H et al. study found no correlation between GPC3 
levels and prognostic parameters. GPC3 was not a 
useful diagnostic and prognostic marker for HCC. 
The sensitivity and specificity of AFP (68.57, 
94.55) were higher than GPC3 (61.33, 41.82).15
In this study, the AUC values of AFP (87.8%) 
was higher than AAG (81.4%). The differences 
of control group may interfere the value of AUC. 
In our study, the control group was patients with 
cirrhosis, in contrast with other studies using 
patients with cirrhosis and chronic hepatitis 
as the control.7,8 In the study by Chio LF and 
Oon CJ6, it was showed that AAG increased in 
20% patients with cirrhosis and only 5.7% in 
patients with chronic hepatitis. Combination 
AFP and AAG obtain the highest AUC values 
(93%) compared to AFP alone and AAG alone. 
Compared to the other serum biomarker that 
has been mentioned previously, the combination 
of AFP and AAG has the best AUC value. The 
AUC value of DCP and AFP-L3% were lower 
than AFP. As well as GPC3 which has lower 
sensitivity and specificity than AFP. Combination 
AFP dan AAG have sensitivity of 78% with NPV 
and PPV were 73% and 91% respectively (at 
specificity 90%).
In the study of our group by Bachtiar 
et al. (2009), 220 patients were included, 
of which 124 had HCC and 61 (49%) of 
them were AFP-low HCC (AFP ≤20 ng/mL). 
The remaining 96 patients, consisted of 49 
with chronic hepatitis B or C and 47 with 
Table 2. Cut-off and ROC curve analysis of AFP, AAG, and combination of AFP and AAG
Test Cut-off AUC (95% CI) P Se Sp NPV PPV
AFP 20.45 ng/ml 86.2% 0.0005 73% 92% 73% 92%
AAG 129 mg/dL 76.5% 0.0005 44% 92% 57% 87%
AFP + AAG 20.45 ng/dl  and/or 129 mg/dL 88.1% 0.0005 85% 83% 81% 86%
Table 3. AUC for combination of AFP + DCP14






cirrhosis, were included into control group. 
Their result showed the combination of AFP and 
AAG have higher sensitivity than AFP alone. 
Compared to previous one, our study is the 
first to specifically differentiate the use of AAG 
and AFP for biomarker screening in cirrhosis 
patients therefore it is more applicable in clinical 
settings since only proven cirrhosis patients were 
included.
Although the research has reached its aims, 
there were some limitations acknowledged. Due 
to the time and cost consideration, this research 
was conducted on small size of population 
using cross sectional design. The subject could 
be divided into groups based on severity of 
cirrhosis to study diagnostic value of AAG, AFP, 
and combination of both AFP and AAG on to 
different levels. Ideally, the number of participant 
would have been more evenly distributed across 
gender but the actual data of HCC prevalence 
was mainly occurred in men.
CONCLUSION
Our study showed comparison between AFP 
alone, AAG alone, and combination of AFP and 
AAG in diagnosing hepatocellular carcinoma in 
liver cirrhosis patients. Liver cirrhosis patients 
with AFP higher than 24.5 ng/ml and AAG higher 
than 130.3 mg/dl were highly associated with 
existence of HCC. Prospective studies on larger 
patients are required to confirm this study. Data 
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from this study may contribute to improve the 
prognosis of HCC patients by enabling early 
diagnosis and screening to provide early prompt, 
if possible, curative treatment.
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